Статья

Immunogenetic predictors of severe covid-19

A. Malkova, D. Kudlay, I. Kudryavtsev, A. Starshinova, P. Yablonskiy, Y. Shoenfeld,
2021

According to an analysis of published data, only 20% of patients with the new coronavirus infection develop severe life-threatening complications. Currently, there are no known biomarkers, the determination of which before the onset of the disease would allow assessing the likelihood of its severe course. The purpose of this literature review was to analyze possible genetic factors characterizing the immune response to the new coronavirus infection that could be associated with the expression of angiotension-converting enzyme 2 (ACE-2) and related proteins as predictors of severe Corona virus disease 2019 (COVID-19). We analyzed original articles published in Medline, PubMed and Scopus databases from December 2019 to November 2020. For searching articles, we used the following keywords: New coronavirus infection, Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), COVID-19, severe course, complications, thrombosis, cytokine storm, ACE-2, biomarkers. In total, 3714 publications were selected using the keywords, of which 8 were in congruence with all the criteria. The literature analysis of the association of immunogenic characteristics and the expression of ACE-2 and related proteins with the development of severe COVID-19 revealed following genetic factors: HLA-B*46:01 genotype, CXCR6 gene hypoexpression, CCR9 gene expression, TLR7, rs150892504 mutations in the ERAP2 gene, overexpression of wild-type ACE-2, TMPRSS2 and its different polymorphisms. Genes, associated with the severe course, are more common among men. According to the analysis data, it can be assumed that there are population differences. However, the diagnostic significance of the markers described must be confirmed with additional clinical studies.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2021-01-01

Метаданные

Об авторах
  • A. Malkova
    Saint Petersburg State University
  • D. Kudlay
    Sechenov First Moscow State Medical University, State Research Center Institute of Immunology FMBA
  • I. Kudryavtsev
    Institute of Experimental Medicine (IEM), Far Eastern Federal University
  • A. Starshinova
    Almazov National Medical Research Centre
  • P. Yablonskiy
    Saint Petersburg State University, Saint-Petersburg State Research Institute of Phthisiopulmonology
  • Y. Shoenfeld
    Saint Petersburg State University, Chaim Sheba Medical Center Israel, Tel Aviv University, Sackler Faculty of Medicine
Название журнала
  • Vaccines
Том
  • 9
Выпуск
  • 3
Страницы
  • 1-13
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus